1. Introduction
===============

Chemotherapy is one of the most commonly used treatment options for malignant tumors, especially for unresectable patients \[[@B1-molecules-17-02351]\]. Improvements in treatment and prevention have led to a decrease in cancer deaths, but the number of new diagnoses continues to rise. New classes of therapies targeting specific proteins perturbed in cancers have been heralded as "smart drugs" that more effectively target the disease than current chemotherapeutic regimes such as doxorubicin, cisplatin and fluorouracil \[[@B2-molecules-17-02351]\]. However, disappointing results in recent clinical trials indicate that a major challenge of target-based drug discovery approaches is overcoming target mechanism heterogeneity among patients and inherent or acquired drug resistance \[[@B3-molecules-17-02351]\]. Consequently, current cancer drug discovery approaches are not appropriately tailored to complex disease mechanism(s) \[[@B4-molecules-17-02351]\]. Phenotypic screening, widely used to find new drugs in old days, is arguably associated with the more humble recognition that you really don't believe you understand the mechanism \[[@B5-molecules-17-02351]\]. If you can establish a way to make a wayward cell less harmful, the mechanism may not matter all that much. Between 1999 and 2008, the contribution of phenotypic screening to the discovery of first-in-class small-molecule drugs exceeded that of target-based approaches-with 28 and 17 of these drugs coming from the two approaches, respectively \[[@B5-molecules-17-02351]\].

Our research group focused our attention on the design, synthesis and cell-based phenotypic screening of novel tumor growth inhibitors and apoptosis inducer as potential anti-proliferative agents. In recent years nitrogen-containing heteroaromatic species of biological significance have attracted considerable research interest as these entities constitute the core structure of numerous pharmaceuticals. Pyrimidine derivatives have shown remarkable activity as PDE4 inhibitors, antileukemia, bronchodilators, vasodilators, antiallergic, antihypertensive and anticancer agents \[[@B6-molecules-17-02351],[@B7-molecules-17-02351],[@B8-molecules-17-02351],[@B9-molecules-17-02351],[@B10-molecules-17-02351],[@B11-molecules-17-02351],[@B12-molecules-17-02351]\]. In the past few years, several synthetic methodologies for 7-aminopyrido\[2,3-*d*\]pyrimidin-6-carbonitrile derivatives have been developed \[[@B13-molecules-17-02351]\]. However, the antitumor activities of these compounds have not been fully explored.

In this article we describe a novel series of N-3-substituted 7-aminopyrido\[2,3-*d*\]pyrimidine-6-carbonitrile derivatives ([Figure 1](#molecules-17-02351-f001){ref-type="fig"}) and a cell-based phenotypic evaluation of their anti-tumor activities by the MTT method. The cell-cycle analysis of the most potent compound **4a** is presented. Their preliminary structure--activity relationships (SARs) are also discussed.

![Structure of 7-amino-pyrido\[2,3-*d*\]pyrimidine-6-carbonitrile derivatives.](molecules-17-02351-g001){#molecules-17-02351-f001}

2. Results and Discussion
=========================

2.1. Chemistry
--------------

The general synthetic approach to the desired final compounds **3a**--**s** is outlined in [Scheme 1](#molecules-17-02351-f006){ref-type="scheme"}.

![Synthetic route of compounds **3a--s**.](molecules-17-02351-g006){#molecules-17-02351-f006}

The core structure of 7-aminopyrido\[2,3-*d*\]pyrimidine-6-carbonitrile derivatives, was built *via* a reported multi-component reaction \[[@B14-molecules-17-02351]\] with minor revisions. Briefly, the key intermediates **2a--i** were readily synthesized in parallel with an appropriate aromatic aldehyde, 6-methyl-1-amino uracil/6-aminouracil and malononitrile as starting materials in the presence of TEBAC. The final compounds **3a--s** were thus obtained by N-3 alkylation of the precursors **2** with R^2^-X in the presence of potassium carbonate in DMF. To note, derivatives **3a--i** and **3r--s** were obtained at 60 °C, whereas the reaction at room temperature was found to be optimal to afford compounds **3j--q**. The structures of **3a--s** were fully characterized and identified by ^1^H-NMR, ^13^C-NMR and HR-MS analyses.

As illustrated in [Scheme 2](#molecules-17-02351-f007){ref-type="scheme"}, to find a more potent compound, derivatives **4a--e** were prepared starting from **2g** or **2j** in the presence of K~2~CO~3~ or triethylamine at room temperature in DMF. Compounds **4a--e** were fully characterized and identified by ^1^H-NMR, ^13^C-NMR and HR-MS before biological evaluation.

![Synthetic route of compounds **4a--e**.](molecules-17-02351-g007){#molecules-17-02351-f007}

2.2. Anti-proliferative Activities
----------------------------------

All the final compounds underwent primary phenotypic screening for their inhibitory activity against A549, HepG2, SW620, Skov-3 and HeLa tumor cells at 40 μM using the MTT assay. For comparison, the data of cisplatin are also included. As shown in [Table 1](#molecules-17-02351-t001){ref-type="table"}, some derivatives (compounds **3j--s**) exerted potent or moderate inhibitory activities against the five assayed tumor cell lines at 40 μM ([Table 1](#molecules-17-02351-t001){ref-type="table"}). The inhibitory activities of most compounds on SW620 cells were slightly more potent than those for human lung carcinoma A549 cells, human hepatocellular liver carcinoma HepG2 cells, human cervical carcinoma epithelial HeLa cells and human ovarian cancer Skov-3 cells. In our initial efforts to search for novel potent anticancer agents, a caffeine moiety, reported to suppress the proliferation of various cancer cell lines and transformed cell lines \[[@B15-molecules-17-02351],[@B16-molecules-17-02351]\], was covalently coupled to the 7-aminopyrido\[2,3-*d*\]pyrimidine-6-carbonitrile scaffold through a two-carbon linker at the N-3 position. Unfortunately, the obtained compound **3a** demonstrated low inhibitory effects on the five tested tumor cell lines. Further modification of compound **3a** with various substituents at the C-5 position of the pyrido\[2,3-*d*\]pyrimidine scaffold showed no improvement in activities.

molecules-17-02351-t001_Table 1

###### 

Inhibition of compounds **3a--s** on five types of tumor cells at 40 μM.

![](molecules-17-02351-i001.jpg)

  Compd.    R^1^   R^2^                             Ar                      IN ^a^ at 40 μM (%)                                    
  --------- ------ -------------------------------- ----------------------- --------------------- ---------- ---------- ---------- ----------
  3a        H      ---                              Phenyl                  9 ± 2.3               10 ± 2.6   NT ^b^     NT         37 ± 3.0
  3b        H      ---                              4-Cl-Ph-                8 ± 1.4               3 ± 1.5    12 ± 2.2   NT         18 ± 2.1
  3c        H      ---                              3,4-di MeO-Ph-          11 ± 0.9              22 ± 0.5   NT         29 ± 2.8   29 ± 2.1
  3d        H      ---                              3-MeO-4-OH-Ph-          13 ± 3.0              9 ± 2.2    18 ± 2.4   10 ± 1.8   20 ± 1.1
  3e        H      ---                              4-Br-Ph-                27 ± 1.2              28 ± 2.9   NT         21 ± 2.8   34 ± 1.6
  3f        Me     ---                              Phenyl                  7 ± 1.7               NT         NT         NT         NT
  3g        Me     ---                              3-MeO-4-OH-Ph-          3 ± 1.3               NT         NT         NT         17 ± 3.1
  3h        Me     ---                              3,4-di MeO-Ph-          10 ± 0.8              16 ± 1.7   NT         17 ± 2.2   23 ± 0.7
  3i        Me     ---                              Thiazolyl               NT                    NT         NT         NT         NT
  3j        Me     2-methylbenzyl                   3,4-di MeO-Ph-          14 ± 2.1              NT         NT         NT         NT
  3k        Me     2-methylbenzyl                   3-MeO-4-(2-Me-BnO)-Ph   85 ± 2.8              26 ± 3.6   NT         28 ± 3.3   9 ± 4.0
  3l        Me     2-methylbenzyl                   Phenyl                  36 ± 0.9              NT         NT         10 ± 3.8   NT
  3m        Me     2-fluorobenzyl                   Phenyl                  48 ± 4.3              52 ± 2.3   32 ± 2.1   20 ± 1.9   NT
  3n        Me     3-fluorobenzyl                   Phenyl                  42 ± 3.1              55 ± 1.1   NT         16 ± 0.5   14 ± 2.8
  3o        Me     2-(4-fluorophenyl)-2-oxoethyl    Phenyl                  38 ± 1.7              22 ± 3.9   8 ± 2.5    24 ± 5.4   23 ± 1.9
  3p        Me     2-(4-methoxyphenyl)-2-oxoethyl   Phenyl                  21 ± 0.9              38 ± 2.8   38 ± 1.0   20 ± 1.4   NT
  3q        Me     Propargyl                        Phenyl                  25 ± 3.7              28 ± 1.6   7 ± 2.9    20 ± 3.3   19 ± 0.8
  3r        Me     Cyclopentyl                      Phenyl                  52 ± 2.2              NT         NT         21 ± 1.7   14 ± 3.6
  3s        Me     Butyl                            Phenyl                  35 ± 1.5              20 ± 1.8   NT         NT         13 ± 4.5
  Cis ^c^   ---    ---                              ---                     72 ± 2.1              68 ± 1.8   67 ± 1.9   80 ± 2.8   80 ± 3.5

^a^IN = inhibition, measured 48 h after treatment with compounds **3a--s** (40 μM). Results are given in concentrations of 40 μM after continuous exposure of 48 h and show means ± SEM values of three-independent experiments. IR = ![](molecules-17-02351-i002.jpg); ^b^NT denotes not tested; ^c^Cis denotes cisplatin.

This finding could have been due to the excessive numbers of hydrophilic nitrogen atoms in the caffeine substituent. Hence, coupling caffeine with the pyrido\[2,3-*d*\]pyrimidine scaffold did not work as expected. Thus, we turned to link more lipophilic groups at N-3 position to investigate whether thus obtained derivatives would inhibit tumor cell proliferation more effectively. Compounds **3j--s**, with certain lipophilic alkyl or aryl groups incorporated into the N-3 position, exhibited higher inhibition values ([Table 1](#molecules-17-02351-t001){ref-type="table"}) as proposed.

To obtain more accurate data on the anti-proliferative activities of derivatives **3j--s**, we conducted an MTT assay against SW620 tumor cells to measure their IC~50~ values. The concentrations of the assayed compound are in a range from 2.5 to 80 μM. As shown in [Table 2](#molecules-17-02351-t002){ref-type="table"}, derivative **3k** was found to be the most potent one against human colon cancer cells SW620 at low micromolar level, with an IC~50~ value of 12.5 μM, comparable to that of cisplatin. However, compound **3k** exhibited extremely poor inhibitory potency for A549, Skov-3, HepG-2 and HeLa cell lines ([Table 1](#molecules-17-02351-t001){ref-type="table"}).

molecules-17-02351-t002_Table 2

###### 

IC~50~ values of compounds **3j--s** on SW620 cells.

  Compd.   IC~50~ ^a^(μM)   Compd.   IC~50~(μM)   Compd.   IC~50~(μM)   Compd.    IC~50~(μM)
  -------- ---------------- -------- ------------ -------- ------------ --------- ---------------
  **3j**   \>80             **3p**   59.6 ± 2.1   **3m**   65.1 ± 1.1   **3s**    \>80
  **3k**   12.5 ± 0.7       **3q**   71.9 ± 1.5   **3n**   79.6 ± 2.7   Cis ^b^   9.5 ± 0.5 ^c^
  **3l**   76.1 ± 1.9       **3r**   29 ± 0.9     **3o**   71.5 ± 1.8             

^a^IC~50~ denotes half maximal inhibitory concentration. Values are means ± SEM of three independent experiments; ^b^Cis denotes cisplatin; ^c^ The IC~50~ value is comparable to the reported in the literature \[[@B17-molecules-17-02351]\].

To find a more potent compound, derivatives **4a--e** were readily prepared starting from **2g** or **2j** in the presence of K~2~CO~3~ or triethylamine at room temperature in DMF ([Scheme 2](#molecules-17-02351-f007){ref-type="scheme"}). Compounds **4a--e** were fully characterized and identified by ^1^H-NMR, ^13^C-NMR and HR-MS before biological evaluation. The IC~50~ values of compounds **4a--e** on SW620 tumor cells are shown in [Table 3](#molecules-17-02351-t003){ref-type="table"}.

molecules-17-02351-t003_Table 3

###### 

IC~50~ values of compounds **4a--e** on SW620 cells.

![](molecules-17-02351-i003.jpg)

  Compd.        R^2^                               R^3^                               R^4^   IC~50~ ^a^(μM)
  ------------- ---------------------------------- ---------------------------------- ------ ----------------
  **4a**        ![](molecules-17-02351-i004.jpg)   ![](molecules-17-02351-i006.jpg)   OMe    6.9 ± 0.4
  **4b**        "                                  "                                  H      \>40
  **4c**        ![](molecules-17-02351-i005.jpg)   ![](molecules-17-02351-i007.jpg)   OMe    \>40
  **4d**        "                                  "                                  H      \>40
  **4e**        H                                  ![](molecules-17-02351-i008.jpg)   OMe    36.8 ± 1.1
  **Cis ^b^**   \-                                 \-                                 \-     9.5 ± 0.5

^a^IC~50~ denotes half maximal inhibitory concentration. Values are means ± SEM of three independent experiments; ^b^Cis denotes cisplatin.

Special emphasis was placed upon SAR studies on the 3-position of the pyrido\[2,3-*d*\]pyrimidine scaffold and 3-, 4-positions of the phenyl(Ar) at the 5-position of the scaffold ([Table 3](#molecules-17-02351-t003){ref-type="table"}). When R^4^ was a methoxy group, R^2^ and R^3^ were substituted by the benzyl or 1-phenylethanone-2-yl group, respectively, and two compounds, **4a** and **4c**, were obtained with notably different IC~50~ values on SW620 cells, 6.9 μM for **4a** and above 40 μM for **4c**. This result suggested that the carbonyl group of the 1-phenylethanone-2-yl substituent decreased anti-proliferative activities. We next investigated if the methoxy group (R^4^) at C-5 position of the pyrido\[2,3-*d*\]pyrimidine scaffold was necessary by removing the methoxy group. Consequently, compound **4b** was synthesized with a hydrogen atom for R^4^, which led to almost total loss of activity ([Table 3](#molecules-17-02351-t003){ref-type="table"}). Thus, a methoxy group of R^4^ plays a crucial part in contributing to biological activities for pyrido\[2,3-*d*\]pyrimidine derivatives.

2.3. Cell-Cycle Analyses
------------------------

Cell-cycle analyses were done by flow cytometric measurements on SW620 cells. annexin V-fluorescein isothiocyanate (FITC) was used as a marker of phosphatidylserine exposure and propidium iodide (PI) as a marker for dead cells. This combination allowed differentiation between early apoptotic cells (annexin V-positive, PI-negative), late apoptotic/necrotic cells (annexin V-positive, PI-positive), and viable cells (annexin V-negative, PI-negative).

![Effects of **4a** on the induction of apoptosis in SW620 cells for 48 h: a, control; b, 5 μM; c, 10 μM; d, 20 μM; e, 40 μM. Cells were stained with annexin V-FITC and PI. The total number of apoptotic cells are the sum of annexin V+/PI− (early apoptotic) and annexin V+/PI+ (late apoptotic/necrotic) cell populations.](molecules-17-02351-g002){#molecules-17-02351-f002}

After treatment with compound **4a** at 0, 5, 10, 20 and 40 μM for 48 h, the percentage of apoptotic cells was 15.11%, 17.06%, 61.12%, 76.33% and 89.26% ([Figure 2](#molecules-17-02351-f002){ref-type="fig"}). These results indicated that the growth inhibition of SW620 cells was caused by inducing apoptosis in a concentration-dependent manner \[[@B18-molecules-17-02351]\].

3. Experimental
===============

3.1. General
------------

Human cancer cell lines were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). Dulbecco's modified Eagle's medium (DMEM) and RPMI 1640 were purchased from Gibco (Grand Island, New York, NY, USA). Fetal bovine serum (FBS) was purchased from Hyclone (Logan, UT, USA). All chemicals were commercially available and used without further purification unless otherwise stated. Column chromatography was carried out on silica gel (400 mesh, Qingdao Marine Chemical Ltd., Qingdao, China). Thin-layer chromatography (TLC) was undertaken on TLC silica gel 60 F254 plates. ^1^H-NMR and ^13^C-NMR spectra were recorded on a Bruker Avance (Varian Unity Inova) 400 MHz spectrometer using TMS as internal reference chemical shift in δ, ppm. Chemical shifts (δ) are reported in parts per million relative to tetramethylsilane (TMS) used as an internal standard, where (δ) TMS = 0.00 ppm. High-resolution mass spectrometry was carried out on a Waters Q-TOF Premier mass spectrometer.

3.2. General Procedure for the Synthesis of ***2a--j***
-------------------------------------------------------

For derivatives **2a--e** ([Figure 3](#molecules-17-02351-f003){ref-type="fig"}), 6-aminouracil (10 mmol) were suspended in ethylene glycol (120 mL) at 100 °C, the appropriate aldehyde (10 mmol) and propanedinitrile (10 mmol) were added in one portion.

![The chemical structure of compounds **2a--e**.](molecules-17-02351-g003){#molecules-17-02351-f003}

After the mixture turned transparent, TEBAC (150 mg) was added to the mixture as phase transfer catalyst. The resultant mixture was stirred at 100 °C for 4--7 h, cooled to room temperature, The mixture was filtered, washed with EtOH, the solids **2a--e** formed were recrystallized from DMF and water. Their physical appearance, melting point and spectroscopic data were in agreement with published data.

For derivatives **2f--j** ([Figure 4](#molecules-17-02351-f004){ref-type="fig"}), 6-amino-1-methyluracil (10 mmol) were suspended in water (120 mL) at 100 °C, aldehyde (10 mmol) and propanedinitrile (10 mmol) were added until the suspension almost cleared up, then the TEBAC (150 mg) was added in the mixture as phase transfer catalyst, the mixture was stirred at 100 °C for 20--24 h, cooled to room temperature, The mixture was filtered, washed with EtOH, the solids **2f--j** formed were recrystallized from DMF and water. Their physical appearance, melting point and spectroscopic data were in agreement with published data.

![The chemical structure of compounds **2f--j**.](molecules-17-02351-g004){#molecules-17-02351-f004}

3.3. The Structure of Reagents R^2^-X ([Figure 5](#molecules-17-02351-f005){ref-type="fig"}) and General Procedure for the Synthesis of 1-(2-Bromoethyl)-3,7-dimethyl-1H-- purine-2,6(3H,7H)-diones
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Anhydrous cesium carbonate (50 mmol) and theobromine (25 mmol) were suspended in DMF (100 mL), after the mixture was stirred at room temperature for 10 min, 1,2-dibromoethane (250 mmol) was added. After completion of the reaction as monitored by TLC, the mixture was poured into water, extracted with ethyl acetate, the organic layer was washed with water twice, and dried with anhydrous sodium sulfate. The combined organic layer was evaporated to obtain a residue which was purified by column chromatography. Its physical appearance and spectroscopic data were in agreement with published data.

![The chemical structure of reagents R^2^-X.](molecules-17-02351-g005){#molecules-17-02351-f005}

3.4. Syntheses of Compounds *3a--s*
-----------------------------------

The corresponding compounds **2**(1 mmol) and anhydrous potassium carbonate were stirred at 60 °C (for **3f--q**, room temperature) in DMF (5 mL), then R^2^-X (1.1 mmol) was added. After completion of the reaction monitored by TLC, the mixture was poured into water (25 mL). It was extracted with dichloromethane (for **3f--q**, ethyl acetate was used). The combined organic layer was washed with water, dried with Na~2~SO~4~, evaporated to obtain a residue, and purified by column chromatography.

*7-Amino-3-(2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)ethyl)-2,4-dioxo-5-phenyl-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3a**) White solid; Yield: 40.1%; ^1^H-NMR (DMSO-d~6~) δ 11.11 (s, 1H), 8.00(s, 1H), 7.65 (s, 2H), 7.41 (d, *J* = 2.4 Hz, 2H), 7.26 (t, *J* = 2.8 Hz, 1H), 7.15 (t, *J* = 3.2 Hz, 2H), 4.47 (s, 2H), 4.26 (s, 2H), 3.79 (s, 3H), 3.35 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 160.78, 159.91, 158.91, 155.46, 155.00, 154.56, 150.99, 150.54, 150.19, 148.17, 142.84, 136.65, 128.23, 127.65, 127.37, 115.24, 106.37, 98.89, 98.22, 88.61, 87.80, 33.08, 29.34; HRMS: calcd. for C~23~H~19~N~9~O~4~^+^ \[M+Na^+^\]: 508.1458, found: 508.1486.

7*-Amino-5-(4-chlorophenyl)-3-(2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)ethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3b**) White solid; Yield: 57.3%; ^1^H-NMR (DMSO-d~6~) δ 11.17 (s, 1H), 8.00 (s, 1H), 7.69 (s, 2H), 7.49 (d, *J* = 8.8 Hz, 2H), 7.19 (d, *J* = 8.8 Hz, 2H), 4.46 (d, *J* = 3.2 Hz, 2H), 4.26 (d, *J* = 3.2 Hz, 2H), 3.79 (s, 3H), 3.35 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 159.83, 158.82, 157.56, 154.99 154.55, 150.98, 150.49, 148.18, 142.84, 135.53, 133.06, 129.41, 127.78, 114.93, 106.37, 98.84, 87.62, 67.19, 60.70, 59.72, 33.08, 29.25, 19.93; HRMS: calcd. for C~23~H~18~ClN~9~O~4~^+^ \[M+Na^+^\]: 542.1068, 544.1038, found: 542.1012, 544.1064.

*7-Amino-5-(3,4-dimethoxyphenyl)-3-(2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)-ethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3c**) White solid; Yield: 32.2%; ^1^H-NMR (DMSO-d~6~) δ 11.09 (s, 1H), 8.00 (s, 1H), 7.58 (s, 2H), 6.99 (d, *J* = 8.4 Hz, 1H), 6.76 (d, *J* = 2 Hz,1H), 6.71 (dd, *J* = 8 Hz, *J* = 2 Hz, 1H), 4.46 (m, 2H), 4.25 (s, 2H), 3.81 (s, 3H), 3.79 (s, 3H), 3.72 (s, 3H), 3.35 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 159.87, 158.73, 155.00, 154.56, 151.00, 150.53, 148.93, 148.71, 147.82, 142.82, 128.73, 120.18, 115.34, 111.79, 110.88, 106.38, 99.03, 88.07, 67.19, 67.15, 60.70, 55.45, 33.07, 29.23, 19.92; HRMS: calcd. for C~25~H~23~N~9~O~6~^+^ \[M+Na^+^\]: 568.1669, found: 568.1703.

*7-Amino-3-(2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)ethyl)-5-(4-hydroxy-3-methoxyphenyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3d**) White solid; Yield: 30.5%; ^1^H-NMR (DMSO-d~6~) δ 11.07 (s, 1H), 9.25 (s, 1H), 7.53 (s, 2H), 6.80 (d, *J* = 8 Hz, 1H), 6.73 (d, *J* = 1.6 Hz, 1H), 6.58 (dd, *J* = 7.6 Hz, *J* = 1.2 Hz, 1H), 4.46 (d, *J* = 19.6 Hz, 2H), 4.25 (s, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 3.35 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 159.88, 159.05, 158.75, 155.02(2C), 150.98, 150.54, 148.18(2C), 146.95, 146.76, 142.82, 127.23, 120.61, 114.83(2C), 112.32, 106.37, 99.03, 88.11, 55.67(2C), 33.07, 29.33; HRMS: calcd. for C~24~H~21~N~9~O~6~^+^ \[M+Na^+^\]: 554.1512, found: 554.1580.

*7-Amino-5-(4-bromophenyl)-3-(2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)ethyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3e**) White solid; Yield: 27.7%; ^1^H-NMR (DMSO-d~6~) δ 11.18 (s, 1H), 8.00 (s, 1H), 7.64 (s, 2H), 7.63 (d, *J* = 8.4 Hz, 1H), 7.13 (d, *J* = 8.4 Hz, 1H), 4,46 (s, 2H), 4.25 (s, 2H), 3.79 (s, 3H), 3.36 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 159.83, 158.83, 157.57, 155.00, 154.56, 150.99, 150.50, 148.19, 142.86, 135.94, 130.76, 129.57, 121.72, 114.93, 106.37, 98.79, 87.53, 59.72(2C), 33.09, 29.34, 20.73, 14.05; HRMS: calcd. for C~23~H~18~BrN~9~O~4~^+^ \[M-H^+^\]: 562.0587, 564.0566, found: 562.0511, 564.0612.

*7-Amino-3-(2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)ethyl)-1-methyl-2,4-dioxo-5-phenyl-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3f**) White solid; Yield: 57.8%; ^1^H-NMR (DMSO-d~6~) δ 8.08 (s, 1H), 7.89 (s, 2H), 7.34 (t, *J* = 7.6 Hz, 1H), 7.25 (t, *J* = 7.6 Hz, 2H), 6.83 (d, *J* = 7.2 Hz, 2H), 4.06 (m, 4H).3.76 (s, 3H), 3.46 (s, 3H), 3.30 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 160.75, 159.89, 158.84, 155.09(2C), 154.15, 151.51, 151.26(2C), 148.81, 143.41, 136.90, 128.49, 127.96, 127.30, 115.68, 106.96, 98.56(2C), 88.90(2C), 33.52, 29.96, 29.74; HRMS: calcd. for C~24~H~21~N~9~O~4~^+^ \[M+Na^+^\]: 522.1614, found: 522.1642.

*7-Amino-3-(2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)ethyl)-5-(4-hydroxy-3-methoxyphenyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3g**) White solid; Yield: 52.1%; ^1^H-NMR (DMSO-d~6~) δ 9.21 (s, 1H), 8.04 (s, 1H), 7.83 (s, 2H), 6.73 (s, 1H), 6.62 (d, *J* = 8.4 Hz, 1H), 6.20 (dd, *J* = 8.4 Hz, *J* = 1.6 Hz, 1H), 4.18 (m, 2H), 3.98 (m, 2H), 3.77 (s, 3H), 3.68 (s, 3H), 3.43 (s, 3H), 3.31(s, 3H); ^13^C-NMR (DMSO-d~6~): δ 160.77, 160.21, 159.08, 155.08, 154.65, 152.05(2C), 148.79, 147.30(2C), 143.96, 127.96, 121.33, 115.10(2C), 112.95, 107.05, 98.81, 88.78, 79.64, 56.08(2C), 33.53, 29.95, 29.77; HRMS: calcd. for C~25~H~23~N~9~O~6~^+^ \[M+Na^+^\]: 568.1669, found: 568.1605.

*7-Amino-5-(3,4-dimethoxyphenyl)-3-(2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl) ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3h**) White solid; Yield: 49.5%; ^1^H-NMR (DMSO-d~6~) δ 8.06 (s, 1H), 7.87 (s, 2H), 7.77 (s, 1H), 6.76 (d, *J* = 8.4 Hz, 1H), 6.35 (dd, *J* = 1.6 Hz, *J* = 8 Hz, 1H), 4.15 (m, 2H), 4.22 (m, 2H), 3.79 (s, 3H), 3.78 (s, 3H), 3.67 (s, 3H), 3.43 (s, 3H), 3.31 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ160.43, 159.84, 158.55, 154.87, 154.13, 151.59, 151.35, 148.81, 148.38, 143.56, 129.52, 120.22, 115.67(2C), 112.13, 106.99, 98.87, 88.40, 79.22, 55.98, 55.86, 33.55, 29.96, 29.78, 21.22, 14.55; HRMS: calcd. for C~26~H~25~N~9~O~6~^+^ \[M+Na^+^\]: 582.1825, found: 582.1877.

*7-Amino-3-(2-(3,7-dimethyl-2,6-dioxo-2,3,6,7-tetrahydro-1H-purin-1-yl)ethyl)-1-methyl-2,4-dioxo-5-(thiophen-2-yl)-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3i**) White solid; Yield: 60.3%; ^1^H-NMR (DMSO-d~6~) δ 8.04 (s, 1H), 7.96 (s, 2H), 7.59 (d, *J* = 4.8 Hz, 1H), 7.01 (t, *J* = 3.2 Hz, 1H), 6.81 (d, *J* = 2.4 Hz, 1H), 4.08 (d, *J* = 5.2 Hz, 4H), 3.77 (s, 3H), 3.44 (s, 3H), 3.31 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 161.03, 158.95, 154.12, 151.05, 149.88, 148.62, 137.76, 136.25, 130.89, 128.43, 128.02, 123.52, 116.83, 112.04, 111.80, 101.62, 90.85, 56.66, 55.89, 45.73, 30.68, 16.98; HRMS: calcd. for C~22~H~19~N~9~O~4~S^+^ \[M+Na^+^\]: 528.1178, found: 528.1096.

*7-Amino-5-(3,4-dimethoxyphenyl)-1-methyl-3-(2-methylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3j**) White solid; Yield: 57.8%; ^1^H-NMR (CDCl~3~) δ 7.12 (s, 1H), 7.11 (d, *J* = 1.2 Hz, 1H), 7.06 (m, 1H), 6.96 (d, *J* = 8 Hz, 2H), 6.90 (dd, *J* = 8 Hz, *J* = 2 Hz, 1H), 6.73 (d, *J* = 2 Hz, 1H), 5.70 (s, 2H), 5.10 (s, 2H), 3.92 (s, 3H), 3.80 (s, 3H), 3.64 (s, 3H);^13^C-NMR (DMSO-d~6~): δ 160.16(2C), 158.77, 154.22, 151.05, 149.88, 148.62, 135.76, 134.44, 130.30, 128.23, 127.02, 125.84, 125.59, 120.20, 115.53, 111.24, 110.70, 100.42, 90.35, 55.89, 55.75, 42.23, 30.27, 19.26; HRMS: calcd. for C~25~H~23~N~5~O~4~^+^ \[M+Na^+^\]: 480.1648, found: 480.1604.

*7-Amino-5-(3-methoxy-4-(2-methylbenzyloxy)phenyl)-1-methyl-3-(2-methylbenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3k**) White solid; Yield: 28.8%; ^1^H-NMR (CDCl~3~) δ 7.46 (d, *J* = 7.2 Hz, 1H), 7.26--7.21 (m, 3H), 7.13 (t, *J* = 2.8 Hz, 2H), 7.10--7.07 (m, 1H), 7.02 (d, *J* = 8.8 Hz, 1H), 6.97 (d, *J* = 7.6 Hz, 1H), 6.88 (dd, *J* = 8 Hz, *J* = 2Hz, 1H), 6.78 (d, *J* = 1.6 Hz, 1H), 5.71 (s, 2H), 5.15(s, 2H), 5.13 (s, 2H), 3.80 (s, 3H), 3.66 (s, 3H), 2.41 (s, 3H), 2.39 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 160.88, 159.84, 158.73, 154.40, 151.28(2C), 148.71, 148.59, 137.28, 135.40, 135.29, 135.26, 130.56, 130.26, 129.97, 129.33, 128.63, 126.91, 126.26, 125.04, 120.46, 116.11, 112.76, 112.47, 99.29, 89.36, 68.96, 55.98, 42.23, 30.24, 19.13, 18.94; HRMS: calcd. for C~32~H~29~N~5~O~4~^+^ \[M-H^+^\]: 546.2141, found: 546.2157.

*7-Amino-1-methyl-3-(2-methylbenzyl)-2,4-dioxo-5-phenyl-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3l**) White solid; Yield: 65.8%; ^1^H-NMR (CDCl~3~) δ 7.48 (t, *J* = 3.2 Hz, 3H), 7.28 (d, *J* = 3.6 Hz, 2H), 7.11 (d, *J* = 3.6 Hz, 2H), 7.07 (m, 1H), 6.90 (d, *J* = 7.6 Hz, 1H), 5.71 (s, 2H), 5.08 (s, 2H), 3.65 (s, 3H), 2.35 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 160.49, 159.92, 158.82, 154.24, 151.32, 150.06, 148.77, 136.18, 135.63, 134.28, 130.26, 129.19, 128.32, 127.07, 126.99, 125.91, 125.35, 115.19, 100.56, 90.60, 42.20, 30.26, 19.21; HRMS: calcd. for C~23~H~19~N~5~O~2~^+^ \[M+H^+^\]: 398.1617, found: 398.1685.

*7-Amino-3-(2-fluorobenzyl)-1-methyl-2,4-dioxo-5-phenyl-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3m**) White solid; Yield: 60.2%; ^1^H-NMR (CDCl~3~) δ 7.51 (t, *J* = 2.8 Hz, 3H), 7.38 (dd, *J* = 8.4 Hz, *J* = 5.2 Hz, 2H), 7.26 (s, 2H), 6.93 (t, *J* = 8.8 Hz, 2H), 5.68 (s, 2H), 5.03 (s, 2H), 3.62 (s, 3H), 2.18 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 160.49, 159.94, 159.87, 158.70, 154.12, 150.80, 136.14, 131.03, 130.98, 129.25, 128.95, 128.92, 128.35, 127.10, 123.98(2C), 115.42, 115.14, 100.37, 90.26, 43.84, 38.67, 30.21; HRMS: calcd. for C~22~H~16~FN~5~O~2~^+^ \[M-H^+^\]: 400.1210, found: 400.1248.

*7-Amino-3-(3-fluorobenzyl)-1-methyl-2,4-dioxo-5-phenyl-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3n**) White solid; Yield: 66.7%; ^1^H-NMR (CDCl~3~) δ 7.51 (t, *J* = 3.2 Hz, 3H), 7.28--7.19 (m, 3H), 7.14 (d, *J* = 7.6 Hz, 1H), 7.05 (d, *J* = 10 Hz, 1H), 6.94--6.89 (m, 1H), 5.70 (s, 2H), 5.05 (s, 2H), 3.63 (s, 3H);^13^C-NMR (DMSO*-*d~6~): δ 163.94, 161.49, 160.47, 159.95, 158.68, 154.07, 150.98, 139.06, 136.21, 129.82, 129.24, 128.35, 127.11, 124.43, 115.62, 115.13, 115.38, 114.41, 100.39, 90.31, 44.09, 30.22; HRMS: calcd. for C~22~H~16~FN~5~O~2~^+^ \[M-H^+^\]: 400.1210, found: 400.1296.

*7-Amino-3-(2-(4-fluorophenyl)-2-oxoethyl)-1-methyl-2,4-dioxo-5-phenyl-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3o**) Yellow solid; Yield: 48.0%; ^1^H-NMR (CDCl~3~) δ 7.95 (dd, *J* = 8.8, *J* = 5.2 Hz, 2H), 7.46 (t, *J* = 3.6Hz, 3H), 7.26 (d, *J* = 9.2Hz, 2H), 7.12 (t, *J* = 8.6 Hz, 2H), 5.74 (s, 2H), 5.32 (s, 2H), 3.66 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 191.68, 166.53, 160.90, 160.12, 158.37, 154.23, 151.00, 137.43, 131.60, 131.53, 128.64, 128.23(2C), 127.68(3C), 116.55, 116.41, 115.65, 98.69, 89.53, 47.82, 30.20; HRMS: calcd. for C~23~H~16~FN~5~O~3~^+^ \[M-H^+^\]: 428.1159, found: 428.1105.

*7-Amino-3-(2-(4-methoxyphenyl)-2-oxoethyl)-1-methyl-2,4-dioxo-5-phenyl-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3p**) Yellow solid; Yield: 45.2%; ^1^H-NMR (CDCl~3~) δ 7.90 (d, *J* = 8.8 Hz, 2H), 7.46 (t, *J* = 4 Hz, 3H), 7.27 (d, *J* = 9.2 Hz, 2H), 6.91 (d, *J* = 8.8 Hz, 2H), 5.73 (s, 2H), 5.32 (s, 2H), 3.86 (s, 3H), 3.67 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 191.11, 164.13, 160.88, 160.11, 158.40, 154.22, 151.03, 137.46, 130.77(2C), 128.63, 128.23(2C), 127.69(2C), 115.68, 114.57(2C), 98.72, 89.50, 56.07(2C), 47.56, 30.18; HRMS: calcd. for C~24~H~19~N~5~O~4~^+^ \[M-H^+^\]: 440.1359, found: 440.1375.

*7-Amino-1-methyl-2,4-dioxo-5-phenyl-3-(prop-2-ynyl)-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3q**) White solid; Yield: 65.7%; ^1^H-NMR (DMSO-d~6~) δ 7.95 (s, 2H), 7.44 (t, *J* = 3 Hz, 3H), 7.25--7.23 (m, 2H), 7.44 (d, *J* = 1.6 Hz, 2H), 3.52 (s, 3H), 3.07 (s, 1H); ^13^C-NMR (DMSO*-*d~6~): δ 160.82, 160.13, 157.85, 154.17, 150.50, 137.52, 128.67, 128.28(2C), 127.69(2C), 115.66, 98.86, 89.41, 79.67, 73.45, 30.67, 30.18; HRMS: calcd. for C~18~H~13~N~5~O~2~^+^ \[M-H^+^\]: 330.0991, found: 330.0916.

*7-Amino-3-cyclopentyl-1-methyl-2,4-dioxo-5-phenyl-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**3r**) White solid; Yield: 48.3%; ^1^H-NMR (CDCl~3~) δ 7.51--7.49 (m, 3H), 7.25 (t, *J* = 4 Hz, 2H), 5.66 (s, 2H), 5.26--5.21 (m, 1H), 3.61 (s, 3H), 2.05--1.99 (m, 2H), 1.90--1.85 (m, 2H), 1.79--1.71 (m, 2H), 1.52--1.48 (m, 2H); ^13^C-NMR (DMSO*-*d~6~): δ 160.73, 160.02, 159.12, 154.08, 150.70, 137.96, 128.48, 128.22(2C), 127.64(2C), 115.80, 99.37, 89.10, 52.83, 29.88, 28.37(2C), 25.66(2C); HRMS: calcd. for C~20~H~19~N~5~O~2~^+^\[M-H^+^\]: 360.1460, found: 360.1436.

*7-Amino-3-butyl-1-methyl-2,4-dioxo-5-phenyl-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbo-nitrile* (**3s**) White solid; Yield: 51.9%; ^1^H-NMR (CDCl~3~) δ 7.50 (t, *J* = 3.6 Hz, 3H), 7.25 (d, *J* = 2.8 Hz, 2H), 5.67 (s, 2H), 3.86 (t, *J* = 7.8 Hz, 2H), 3.64 (s, 3H), 1.56--1.48 (m, 2H), 1.31--1.25 (m, 2H), 0.89--0.86 (m, 3H); ^13^C-NMR (DMSO*-*d~6~): δ 160.23, 159.80, 158.64, 154.01, 151.00, 136.37, 129.14, 128.31(2C), 127.00(2C), 115.26, 100.59, 90.06, 41.69, 30.10, 29.74, 20.15, 13.75; HRMS: calcd. for C~19~H~19~N~5~O~2~^+^ \[M-H^+^\] m/z 348.1460, found: 348.1488.

3.5. Synthesis of Compounds *4a--d*
-----------------------------------

Compounds **2g** or **2j** (1 mmol) and anhydrous potassium carbonate were stirred at room temperature in DMF (5 mL). Reagents 1-(bromomethyl)-4-fluorobenzene or 2-bromo-1-(4-methoxyphenyl) ethanone (2.1 mmol) were added. After monitoring the completion of the reaction by TLC, the mixture was poured into water (25 mL). It was extracted with EA. The combined organic layer was washed with water, dried with Na~2~SO~4~, evaporated to obtain a residue, that was purified by column chromatography.

*7-Amino-3-(4-fluorobenzyl)-5-(4-(4-fluorobenzyloxy)-3-methoxyphenyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**4a**) White solid; Yield: 27.2%; ^1^H-NMR (CDCl~3~) δ 7.47--7.40 (m, 4H), 7.08 (t, *J* = 8.6 Hz, 2H), 7.00 (d, *J* = 8.4 Hz, 1H), 6.94 (t, *J* = 8.8 Hz, 2H), 6.84 (dd, *J* = 8.4 Hz, *J* = 2 Hz, 1H), 7.75 (d, *J* = 2 Hz, 1H), 5.67 (s, 2H), 5.15 (s, 2H), 5.05 (s, 2H), 3.83 (s, 3H), 3.62 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 163.04, 162.44, 160.62, 160.33, 160.03, 159.29, 158.17, 153.77, 150.78, 148.18, 147.93, 133.38, 133.24, 133.21, 130.25, 130.17, 129.64, 119.97, 115.56, 115.33, 115.12, 114.99, 114.78, 112.36, 112.06, 98.74, 88.91, 69.13, 55.51, 29.69; HRMS: calcd. for C~30~H~23~F~2~N~5~O~4~^+^ \[M+H^+^\]: 556.1796, found: 556.1856.

*7-Amino-3-(4-fluorobenzyl)-5-(4-(4-fluorobenzyloxy)phenyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido-\[2,3-d\]pyrimidine-6-carbonitrile* (**4b**) White solid; Yield: 24.6%; ^1^H-NMR (CDCl~3~) δ 7.55 (t, *J* = 7.6 Hz, 1H), 7.36--7.00 (m, 11H), 5.72 (s, 2H), 5.20 (s, 2H), 5.19 (s, 2H), 3.64 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 161.47, 160.30, 159.71, 158.82, 154.20, 150.79, 129.95, 129.88, 129.82, 129.04, 128.95, 128.43, 124.34, 123.98, 123.96, 123.88, 123.78, 123.64, 123.54, 115.48, 115.34, 115.32, 114.44, 100.40, 90.39, 63.64, 63.61, 38.71, 30.24; HRMS: calcd. for C~29~H~21~F~2~N~5~O~3~^+^ \[M+H^+^\]: 526.1691, found: 526.1675.

*7-Amino-5-(3-methoxy-4-(2-(4-methoxyphenyl)-2-oxoethoxy)phenyl)-3-(2-(4-methoxyphenyl)-2-oxo-ethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**4c**) White solid; Yield: 28.1%; ^1^H-NMR (DMSO-d~6~) δ 8.01 (dd, *J* = 8.8 Hz, *J* = 6.8 Hz, 4H), 7.07 (dd, *J* = 8.4 Hz, *J* = 5.2 Hz, 4H), 6.90--6.85 (m, 2H), 6.73(dd, *J* = 8.8 Hz, *J* = 2 Hz, 1H), 5.50 (s, 2H), 5.23 (s, 2H), 3.85 (s, 6H), 3.74 (s, 3H), 3.53 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 193.22, 191.18, 164.14, 164.02, 160.90, 159.84, 158.36, 154.22, 151.04, 148.50, 148.10, 130.77(4C), 130.01, 127.77, 127.71, 120.37, 115.97, 114.59(2C), 114.50(2C), 112.97, 112.64, 98.88, 89.67, 70.87, 56.13, 56.07, 47.61, 30.18; HRMS: calcd. for C~34~H~29~N~5~O~8~^+^\[M+Na^+^\]: 658.1914, found: 658.1896.

*7-Amino-5-(4-(2-(4-methoxyphenyl)-2-oxoethoxy)phenyl)-3-(2-(4-methoxyphenyl)-2-oxoethyl)-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidine-6-carbonitrile* (**4d**) White solid; Yield: 21.7%; ^1^H-NMR (DMSO-d~6~) δ 8.01 (t, *J* = 9.2 Hz, 4H), 7.17 (d, *J* = 8.8 Hz, 2H), 7.10--7.03 (m, 4H), 6.96 (d, *J* = 8.8 Hz, 2H), 5.53 (s, 2H), 5.22 (s, 2H), 3.86 (s, 6H), 3.53 (s, 3H); ^13^C-NMR (DMSO-d~6~): δ 193.14, 191.15, 164.13, 164.03, 160.90, 160.50, 159.94, 158.58, 158.45, 158.14, 154.26, 151.02, 130.79(2C), 130.73(2C), 129.63, 129.46, 129.39, 127.72, 127.68, 114.98, 114.54(2C), 114.30(2C), 98.82, 89.66, 70.33, 56.07(2C), 47.58, 30.19; HRMS: calcd. for C~33~H~27~N~5~O~7~^+^ \[M+H^+^\]:606.1989, found: 606.1971.

3.6. Synthesis of Compound *4e*
-------------------------------

Compound **2g** (1 mmol) and TsCl (2.1 mmol) were dissolved in DMF (5 mL) followed by the addition of triethylamine (3 mmol). The mixture was stirred at room temperature for 24 h. The reaction mixture was poured into water and extracted with DCM. The combined organic layer were washed with water and evaporated to half of its volume. The organic layer was cooled to room temperature, and the solid filtered and washed with EtOH to obtain *4-(7-amino-6-cyano-1-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido\[2,3-d\]pyrimidin-5-yl)-2-methoxy phenyl-4-methylbenzenesulfonate* (**4e**) White solid; Yield: 57.0%; ^1^H-NMR (DMSO-d~6~) δ 11.24 (s, 1H), 7.89 (s, 2H), 7.62 (d, *J* = 8.4 Hz, 2H), 7.42 (d, *J* = 8 Hz, 2H), 7.21 (d, *J* = 8 Hz, 1H), 6.92 (d, *J* = 1.6 Hz, 1H), 6.84 (dd, *J* = 8.4 Hz, *J* = 1.6 Hz, 1H), 3.42 (s, 3H), 3.34 (s, 3H), 2.41 (s, 3H); ^13^C-NMR (DMSO*-*d~6~): δ 162.77, 160.74, 159.24, 158.29, 155.40, 151.15, 150.96, 145.90, 137.86, 137.74, 132.21, 130.15, 128.74, 123.57, 120.31, 115.66, 113.28, 99.70, 88.48, 56.07, 36.24, 29.12, 21.62; HRMS: calcd. for C~23~H~19~N~5~O~6~S^+^ \[M+H^+^\]: 494.1134, found: 494.1108.

3.7. Cell Proliferation Assay (MTT Assay)
-----------------------------------------

Briefly, cells (2,500/well) were seeded in 96-well plates and cultured for 24 h, followed by treatment with target compounds for a further 48 h. Twenty microlitres of 5 mg/mL MTT was added per well and incubated for a further 2.5 h at 37 °C. Then the supernatant was removed, and 150 μL/well DMSO added for 15--20 min. The optical density of each well was measured at 570 nm using a SpectraMAX M5 microplate spectrophotometer (Molecular Devices, Silicon Valley, CA, USA).

3.8. Apoptosis Analyses
-----------------------

Briefly, 1.5 × 10^5^ cells were seeded per well in a six-well plate. Twenty-four hours later, cells were treated with **4a** for a further 48 h. All cells were collected, washed twice with phosphate-buffered saline (PBS) and resuspended in 100 μL binding buffer. Then cell suspensions were mixed with 5 μL annexin V-FITC and 10 μL PI, and incubated for 15 min in the dark at room temperature. After staining, 400 μL of binding buffer was added and stained cells analyzed using a flow cytometer.

4. Conclusions
==============

Twenty-four novel N-3 substituted 7-aminopyrido\[2,3-*d*\]pyrimidin-6-carbonitrile derivatives were synthesized and evaluated as potential anticancer agents through a cell-based phenotypic screening approach. Compound **3k** was found to exhibit significant potency against human colon cancer cells SW620 with an IC~50~ value of 12.5 μM. Further structural modification led to a more potent compound **4a** with an IC~50~ value of 6.9 μM, which is slightly more potent than cisplatin against SW620 tumor cells. Preliminary SARs information suggested that lipophilic groups at N-3 position are preferred and a methoxy group at the R^4^-position plays a crucial part. Flow cytometric analyses indicated that compound **4a** acts through induction of apoptosis in human colon cancer SW620 cells. The underlying mechanism of action of compound **3k** and **4a** will further examined in our lab.
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